Ojas Agarwal secured 96%, Aditi Agarwal 94.2%, Ashutosh Pawar 93.6%, Utkarsh Agarwal 93.4%, Tanishka Patel 92.8%, Jawwad Khan ...

This company is operating at the intersection of India’s massive education economy and the country’s growing obsession with ...

The NEET scandal has exposed more than just leaked papers and broken exam systems. It has revealed the terrifying desperation ...

Consumers across the country reacted sharply to the increase, with many expressing concerns about rising household expenses and inflation.

CISCE announced ICSE and ISC results with near-perfect pass rates: 99.78% for Class 10 and 99.66% for Class 12 in NCR, with girls outperforming boys.

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

Snabbit secures $56M in Series D funding led by Susquehanna, Mirae, and Bertelsmann. Plans to expand services and enter new ...

The Registrar of Companies found that the company remained without a whole-time Company Secretary from 2014 to 2020 in ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...